SHARE

AstraZeneca targets $80bn in revenue by 2030

The pharmaceuticals giant has said that it is aiming to generate $80bn in revenue by 2030, nearly double the $45.8bn it made last year. AstraZeneca has said growth will come from its existing oncology, biopharmaceuticals and rare disease portfolios.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.